Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ECO-RESET: A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis

Trial Profile

ECO-RESET: A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SER 287 (Primary) ; Vancomycin
  • Indications Ulcerative colitis
  • Focus Registrational; Therapeutic Use
  • Acronyms ECO-RESET
  • Sponsors Seres Therapeutics
  • Most Recent Events

    • 02 May 2019 According to a Seres Therapeutics media release, if this trial results are positive, the study could serve as one of two pivotal trials to enable a SER-287 Biologics License Application (BLA) submission.
    • 02 May 2019 According to a Seres Therapeutics media release, the company expects to complete enrolment in this trial by mid-2020 and top-line data is expected in 3Q 2020.
    • 28 Nov 2018 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top